These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18359095)

  • 1. Preservation of beta-cell function by targeting beta-cell mass.
    de Koning EJ; Bonner-Weir S; Rabelink TJ
    Trends Pharmacol Sci; 2008 Apr; 29(4):218-27. PubMed ID: 18359095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of beta-cell management in type 2 diabetes.
    Standl E
    Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic approaches to preserve islet mass in type 2 diabetes.
    Baggio LL; Drucker DJ
    Annu Rev Med; 2006; 57():265-81. PubMed ID: 16409149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.
    Lupi R; Del Prato S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S56-64. PubMed ID: 18640587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis.
    Fan R; Li X; Gu X; Chan JC; Xu G
    Diabetes Obes Metab; 2010 Sep; 12(9):815-24. PubMed ID: 20649634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo.
    Uhles S; Wang H; Bénardeau A; Prummer M; Brecheisen M; Sewing S; Tobalina L; Bosco D; Wollheim CB; Migliorini C; Sebokova E
    Diabetes Obes Metab; 2011 Apr; 13(4):326-36. PubMed ID: 21205124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival.
    Buteau J
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S73-7. PubMed ID: 18640589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta cells in type 2 diabetes - a crucial contribution to pathogenesis.
    Maedler K
    Diabetes Obes Metab; 2008 May; 10(5):408-20. PubMed ID: 17451426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Islet inflammation in type 2 diabetes: from metabolic stress to therapy.
    Donath MY; Schumann DM; Faulenbach M; Ellingsgaard H; Perren A; Ehses JA
    Diabetes Care; 2008 Feb; 31 Suppl 2():S161-4. PubMed ID: 18227479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention.
    Karaca M; Magnan C; Kargar C
    Diabetes Metab; 2009 Apr; 35(2):77-84. PubMed ID: 19251449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. beta-cell function and anti-diabetic pharmacotherapy.
    Del Prato S; Bianchi C; Marchetti P
    Diabetes Metab Res Rev; 2007 Oct; 23(7):518-27. PubMed ID: 17883249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretins: a new treatment option for type 2 diabetes?
    Geelhoed-Duijvestijn PH
    Neth J Med; 2007 Feb; 65(2):60-4. PubMed ID: 17379930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth.
    Holloway AC; Hettinga BP; Gerstein HC
    J Diabetes; 2011 Mar; 3(1):74-81. PubMed ID: 21040499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
    Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.